Skip to main content
OpenTrials

Clinical trial condition

Respiratory Hypersensitivity

Explore clinical trials studying Respiratory Hypersensitivity. Study availability and eligibility vary by location and protocol.

4,455 public trials 324 recruiting studies
Refine in advanced search Browse all conditions

Respiratory Hypersensitivity trial results

Completed

Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma

NCT00467740

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • 1222.6.064 Arthur F. Gelb Medical Corporation, Lakewood Lakewood, California, United States
  • 1222.6.062 Boehringer Ingelheim Investigational Site Los Angeles, California, United States
  • 1222.6.066 Allergy & Asthma Medical Group and Rsrch Ctr, APC San Diego, California, United States
  • 1222.6.069 Allergy Associates Medical Group San Diego, California, United States
View all 37 locations
View Trial Details
Completed

A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

NCT01013753

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • 1222.27.43002 Boehringer Ingelheim Investigational Site Linz, Austria
  • 1222.27.43004 Boehringer Ingelheim Investigational Site Schlüsslberg, Austria
  • 1222.27.43001 Boehringer Ingelheim Investigational Site Thalheim bei Wels, Austria
  • 1222.27.43003 Boehringer Ingelheim Investigational Site Vienna, Austria
View all 27 locations
View Trial Details
Completed

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.

NCT00452400

Conditions
Asthma, Bronchial Diseases, Chronic Disease, +11 more
Locations
  • 1222.5.03 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 1222.5.07 Boehringer Ingelheim Investigational Site Lakewood, California, United States
  • 1222.5.14 Boehringer Ingelheim Investigational Site Denver, Colorado, United States
  • 1222.5.13 Boehringer Ingelheim Investigational Site Wheat Ridge, Colorado, United States
View all 42 locations
View Trial Details
Completed

AZISAST Study: AZIthromycin in Severe ASThma Study

NCT00760838

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • Onze Lieve Vrouw Ziekenhuis Aalst Aalst, Belgium
  • ZNA Middelheim Antwerp, Belgium
  • AZ Sint-Jan Brugge Bruges, Belgium
  • Ghent University Hospital Ghent, Belgium
View Trial Details
Completed

Biomarkers of Cockroach Sublingual Immunotherapy 2

NCT01380327

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +12 more
Locations
  • Children's Memorial Hospital Chicago, Illinois, United States
  • Johns Hopkins University School of Medicine Baltimore, Maryland, United States
  • Henry Ford Health System Detroit, Michigan, United States
  • Cincinnati Children's Hospital Cincinnati, Ohio, United States
View Trial Details
Completed

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

NCT01172808

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • 205.418.01020 Boehringer Ingelheim Investigational Site Huntington Beach, California, United States
  • 205.418.01002 Boehringer Ingelheim Investigational Site Mission Viejo, California, United States
  • 205.418.01014 Boehringer Ingelheim Investigational Site San Diego, California, United States
  • 205.418.01011 Boehringer Ingelheim Investigational Site Wheat Ridge, Colorado, United States
View all 114 locations
View Trial Details
Completed

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

NCT01172821

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • 205.419.01058 Boehringer Ingelheim Investigational Site Los Angeles, California, United States
  • 205.419.01053 Boehringer Ingelheim Investigational Site Stockton, California, United States
  • 205.419.01061 Boehringer Ingelheim Investigational Site Centennial, Colorado, United States
  • 205.419.01066 Boehringer Ingelheim Investigational Site Denver, Colorado, United States
View all 125 locations
View Trial Details

Related conditions